Tela Bio, Acelity ’ s LifeCell settle patent spat

Tela Bio and Acelity subsidiary LifeCell settled their patent infringement beef last month for terms that were not disclosed. Malvern, Pa.-based Tela Bio said the settlement puts to bed all state and federal court cases between the companies and allows it to keep making its OviTex line of reinforced scaffolds for abdominal surgery. “We are very pleased that we were able to achieve a satisfactory resolution to all litigations and disputes between Tela Bio and LifeCell,” president & CEO Antony Koblish said in prepared remarks. “With this successful action,Tela Bio is now free to focus on our strategy to advance our commercial plan for our portfolio of 6 OviTex products in an environment of fair competition and further develop our robust product pipeline to expand our offerings for surgeons and patients.” “We are pleased that all litigation and disputes have been resolved and can now return or focus on expanding our proprietary technology. The LifeCell portfolio leads the industry in quality and efficacy and is differentiated by proven clinical results; we look forward to expanding upon this leadership position and delivering more solutions for surgeons and their patients,” LifeCell spokesman Cheston Turbyfill told MassDevice.com today via email. Tela Bio won 510(k) clearance from the FDA in July for the Ovitex portfolio, consisting of scaffolds designed for ventral hernia repair and abdominal wall construction. “TEL...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Legal News Surgical Acelity LifeCell Corp. Tela Bio Source Type: news